Preclinical evaluation demonstrates antitumor activity of a B7-H4-targeting antibody-drug conjugate in resistant breast cancer models, suggesting therapeutic promise against refractory tumors.
Statistical summary of B7-H4-ADC activity in xenograft models and activity in breast cancer PDX models.
No takes yet. Share an insight, caveat, or question.
Gitto et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: